MENU
SGMT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SGMT stock forecast, quote, news & analysis

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate... Show more

A.I.Advisor
published price charts
SGMT
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for SGMT with price predictions
Oct 05, 2026

SGMT's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for SGMT moved out of overbought territory on August 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In 16 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SGMT as a result. In 42 of 51 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for SGMT turned negative on August 31, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In 26 of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.

SGMT moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SGMT crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 7 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGMT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +9.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SGMT advanced for three days, in 151 of 177 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

SGMT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 90 of 109 cases where SGMT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.412) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (75.758) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. SGMT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGMT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 58 to 133.74B. VRTX holds the highest valuation in this group at 133.74B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -14%, and the average quarterly price growth was -3%. LONA experienced the highest price growth at 94%, while KPTI experienced the biggest fall at -59%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 48%. For the same stocks of the Industry, the average monthly volume growth was 88% and the average quarterly volume growth was 11%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
SGMT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
155 Bovet Road
Phone
+1 650 561-8600
Employees
16
Web
https://www.sagimet.com
SGMT's RSI Indicator recovers from overbought zone